Bayer: phase III study for finerenone
(CercleFinance.com) - Bayer is expanding its clinical development program for finerenone with a Phase III study in patients with heart failure and preserved ejection fraction.
FINEARTS-HF is the first large-scale, long-term study to investigate finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, on morbidity and mortality outcomes in a heart failure patient population.
"No treatment is currently approved for patients with heart failure and preserved ejection fraction. These patients are at substantial risk for cardiovascular events, which represents a huge unmet need for cardiovascular disease," said Scott D Solomon.
"The FINEARTS-HF study will assess whether finerenone leads to a reduction in the risk of cardiovascular death and other heart failure events in these underserved patients."
Copyright (c) 2020 CercleFinance.com. All rights reserved.
FINEARTS-HF is the first large-scale, long-term study to investigate finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, on morbidity and mortality outcomes in a heart failure patient population.
"No treatment is currently approved for patients with heart failure and preserved ejection fraction. These patients are at substantial risk for cardiovascular events, which represents a huge unmet need for cardiovascular disease," said Scott D Solomon.
"The FINEARTS-HF study will assess whether finerenone leads to a reduction in the risk of cardiovascular death and other heart failure events in these underserved patients."
Copyright (c) 2020 CercleFinance.com. All rights reserved.